# OnCo record lymphoma-tx-uk-versus-us (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/lymphoma-tx-uk-versus-us/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "lymphoma-tx-uk-versus-us" ;
  schema:name "British and American lymphoma practice: where they differ, and why"@en ;
  schema:alternateName "NICE against NCCN"@en, "UK lymphoma practice"@en, "US lymphoma practice"@en ;
  schema:description "The same trials are read in both countries and reach different conclusions, because the British system asks what a treatment costs for the benefit it gives and the American one asks whether it is better at all. This is a list of the places where a patient's treatment would genuinely differ."@en ;
  schema:url <https://onco.cc/terms/lymphoma-tx-uk-versus-us/> ;
  schema:dateModified "2026-09-29"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(25)01432-1>, <https://doi.org/10.1056/NEJMoa2201817>, <https://www.nccn.org/guidelines/category_1>, <https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-haematological-malignancies> ;
  onco:cancers <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/polatuzumab-vedotin/> ;
  onco:terms <https://onco.cc/terms/lymphoma-tx-uk-access/>, <https://onco.cc/terms/lymphoma-tx-cns-prophylaxis/>, <https://onco.cc/terms/cancer-drugs-fund/> ;
  onco:trials <https://onco.cc/trials/swog-s1826/>, <https://onco.cc/trials/hd21/>, <https://onco.cc/trials/rathl/>, <https://onco.cc/trials/triangle/>, <https://onco.cc/trials/polarix/> .